Kornimate/medical-research-clean huggingface dataset:
regulation of craving in internet gamers

Conditions: Internet Gaming Disorder

Summary: this project aims to investigate (1) the behavioral and neural mechanisms of regulation of craving in internet gamers; (2) effects of tdcs over the dorsal lateral prefrontal cortex (dlpfc) on craving and regulation of craving and aversive emotions in this population. (3) effects of tdcs over dlpfc on attentional bias towards gaming related cues.this project will be conducted in beijing, china, based on a large sample of internet gamers.

as with the experiment about tdcs effects on regulation of craving and aversive emotions, the experiment aims to test whether tdcs over dlpfc will enhance cognitive regulation of craving and aversive emotions. it is a within-subject, sham-controlled, double-blind design. each participant receive both active and sham tdcs of dlpfc in a randomized order separated by one week. during both active and sham tdcs sessions, participants will perform regulation of craving (roc) and emotion regulation (er) tasks. in the roc task, participants will be asked to downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. in the er task, participants will be asked to downregulate and upregulate aversive feelings elicited by negative pictures using cognitive reappraisal. during these tasks, self-report ratings and skin conductance responses (scrs) will be recorded. the cognitive regulation ability is indexed by rating and scrs differences between the up- and downregulation conditions. as with the experiment about tdcs effects on attentional bias, the experiment aims to test whether tdcs over dlpfc will enhance inhibitory control of attentional bias towards gaming related cues. the inhibitory control of attentional bias will be measured by a cognitive task in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. the experiment is a within-subject, sham-controlled, double-blind design. each participant will receive both active and sham tdcs of dlpfc in a randomized order separated by one week. after each tdcs session, participants will complete the cognitive task assessing inhibitory control of attentional bias. during the task, reaction times (rts) wil be recorded. the attentional bias is indexed by rts differences between trials with gaming pictures and trials with non-gaming pictures.

Eligibility criteria:
inclusion criteria: * engagement in a popular internet game (arena of valor) for over 14 hours per week for a minimum of 6 months. exclusion criteria: * current or history of use of illegal substances and gambling; * current or history of psychiatric or neurological illness; * current use of psychotropic medications.
characterization of dynamic stability in normal pressure hydrocephalus and parkinson's disease

Conditions: Hydrocephalus; Parkinson Disease; Walking, Difficulty; Movement Disorders; Gait Ataxia; Diagnoses Disease

Summary: this study aims to characterize dynamic stability disorders in two conditions mainly affecting the elderly and with similar walking deficits: hydrocephalus at normal pressure and parkinson's disease, to provide the most relevant monitoring criteria in usual care.

walking disorders in normal pressure hydrocephalus are manifested by slowing and ataxic gait, similar to disorders in parkinson's disease. no studies in the literature have focused on advanced measures of dynamic stability in hydrocephalus at normal pressure, compared to parkinson's disease, on large samples. the laboratory of analysis and restoration of movement, located in a neurorehabilitation department, provides quantitative data on gait and in particular dynamic stability as part of additional assessments to help patients follow up. since 2010, people with normal pressure hydrocephalus or parkinson's disease regularly benefit from these assessments. retrospective analysis of all these data would help to better characterize motor disorders in hydrocephalus at normal pressure, by discriminating them from those associated with parkinson's disease. it would lead to the definition of relevant indices to be used for patient follow-up.

Eligibility criteria:
inclusion criteria: * age \>18 years * patient who performed a walking test in the laboratory analysis and restoration of movement * diagnosis of normal pressure hydrocephalus or parkinson's disease exclusion criteria: * levodopa drugs administrated during a delay of 12 hours before walking test * presence of an other neurologic disease or of any disease associated with motor disorders in lower limb.
the leaflex™ early feasibility study

Conditions: Aortic Valve Stenosis

Summary: a prospective, multicenter, single-arm, early feasibility study aimed to assess safety and performance of the leaflex™ performer in the treatment of patients with symptomatic, severe aortic stenosis. subjects will be seen at pre- and post procedure, discharge, 30 days and at 3, 6, 9 and 12 months post procedure.


Eligibility criteria:
inclusion criteria: * patient with symptomatic, severe aortic stenosis who are operable, but not recommended by the heart team for immediate treatment with surgical or transcatheter aortic valve replacement. * patient is willing to comply with scheduled visits and tests and is able and willing to provide informed consent. exclusion criteria: * inoperable for emergency surgery. * moderate or greater aortic regurgitation. * anatomic contraindications. * coronary, carotid, or vertebral artery disease that, in the opinion of the heart team, should be treated; or treatment of coronary artery disease ≤ 1 month prior to index procedure. * aortic balloon valvuloplasty ≤ 3 months prior to index procedure. * stroke ≤ 12 months prior to index procedure. * history of a myocardial infarction ≤ 6 weeks prior to index procedure. * patients with clinically significant abnormality in cell blood count, history of bleeding diathesis or coagulopathy. * hemodynamic instability. * hypertrophic cardiomyopathy with obstruction. * left ventricle ejection fraction \<30%. * ongoing severe infection, including endocarditis, or sepsis. * life expectancy ≤ 12 months.
pain outcomes of non-opioid vs. opioid analgesia for kidney stone surgery.

Conditions: Nephrolithiasis

Summary: there are two options for postoperative pain management: opioid and non-opioid analgesia. pain outcomes will be compared in patients undergoing ureteroscopy and percutaneous nephrolithotomy by randomly administering opioid and non-opioid analgesia.

perioperative pain is often managed by opioids. however, post surgical pain management with opioids can often lead to long-term opioid use; additionally, opioids can cause unwanted side effects including respiratory depression that can lead to hypoxia and respiratory arrest, as well as nausea, vomiting, pruritus, ileus, and constipation. as an alternative to opioid perioperative pain management, non-opioid analgesia has been proven to be as effective as opioid management in acute pain. nonsteroidal anti-inflammatory drugs (nsaids) and acetaminophen are often utilized as alternatives to opioid analgesia, and have an increased efficacy when combined. both nsaids and acetaminophen have been proven to decrease opioid requirements and have minimized opiate-induced adverse events. in this randomized clinical trial, pain outcomes after ureteroscopy and percutaneous nephrolithotomy will be investigated in patients who are treated with opioids versus a non-opioid regimen of ketorolac and acetaminophen. percutaneous nephrolithotomy and ureteroscopy are minimally invasive surgical techniques to surgically remove kidney stones. this trial will seek to determine whether non-opioid therapy is noninferior to opioid therapy in the determination of pain intensity as measured by an 11-point numeric rating scale, in which 0 indicates no pain and 10 indicates the worst possible pain, one week after the surgery by telephone call.

Eligibility criteria:
inclusion criteria: * men and women age\>18 years old * presence of renal or ureteral stones suitable for ureteroscopy or percutaneous nephrolithotomy. * uncomplicated ureteroscopy or percutaneous nephrolithotomy exclusion criteria: * pregnant/breastfeeding/possibly pregnant patients * pediatric patients * sensitive or allergic to opioids, ketorolac, or acetaminophen * significant renal disease * peptic ulcer disease * chronic pain and recovering opiate use * inability to complete questionnaires * non-mobile patients * patients on methadone

Keywords: pain outcomes ureteroscopy percutaneous nephrolithotomy opioids
study on chinese and western medicine in mne children

Conditions: Monosymptomatic Nocturnal Enuresis

Summary: monosymptomatic nocturnal enuresis (mne) is a common pediatric developmental disorder. mne refers to urinary incontinence in the sleep state in children aged ≥5 years, without other lut symptoms, and without bladder dysfunction. its pathogenesis mainly include overnight polyuria, overactive bladder, sleep-arousal dysfunction, genetics, and abnormal secretion of anti-diuretic hormone (adh). desmopressin is a synthetic analog of adh arginine-vasopressin (avp), which is used to treat central diabetes insipidus and primary nocturnal enuresis (pne). desmopressin decreases urine production at night when taken at bedtime. insufﬁcient adh secretion at night will contribute to nocturnal polyuria, which is an important cause of ne. therefore, desmopressin, a synthetic analog of adh, is frequently used for ne and is an evidence-based therapy (grade ⅰa evidence). some children, however, have desmopressin resistance and do not achieve the desired treatment goals. what's more,there's a high relapse rate of desmopressin after withdrawing. suoquan mixture is a chinese medicine commonly used to treat ne in children. it is composed of cuscuta, codonopsis, psoralea corylifolia linn ,astragalus,mantis egg-case and ephedra. it has not only a certain cure rate but also has a lower relapse rate . however there's few evidence could prove that. in this study,the investigators compared the 3 month treatment response and relapse rate (rr) in the following 6 months of desmopressin and desmopressin plus suoquan, and observe if there will be a lower relapse rare in desmopressin plus suoquan. moreover, the investigators will try to explore the mechanism of suoquan mixture in mne.


Eligibility criteria:
inclusion criteria: * bedwetting occured ≥2nights/week,last for at least 3 months * without other lut symptoms * without bladder dysfunction. * no treatment in last 3 months * signed the consent exclusion criteria: * had other lut symptoms * with bladder dysfunction * had treatment in last 3 months * without the consent

Keywords: nocturnal enuresischildren chinsese medicine children relapse rate
an open label extension study of cannabidiol (gwp42003-p) in children and adults with dravet or lennox-gastaut syndromes

Conditions: Epilepsy; Dravet Syndrome; Lennox-Gastaut Syndrome

Summary: to investigate the potential antiepileptic effects of cannabidiol (gwp42003-p) in children and adults with dravet or lennox-gastaut syndromes.

this is a multi-center, open-label extension study for participants with dravet syndrome or lennox-gastaut syndrome who have previously participated in double-blind, placebo-controlled clinical studies of gwp42003-p (core studies: gwep1332a \[nct02091206\], gwep1332b \[nct02091375\], gwep1424 \[nct02224703\], gwep1414 \[nct02224560\], gwep1424 \[nct02224703\], and gwep1423 \[nct02224690\]). the first participant was enrolled into the open-label extension study after the data safety monitoring committee reviewed the safety data from part a of study gwep1332.

Eligibility criteria:
key inclusion criteria: • participant has completed the treatment phase of their core studies: gwep1332a \[nct02091206\], gwep1332b \[nct02091375\], gwep1424 \[nct02224703\], gwep1414 \[nct02224560\], gwep1424 \[nct02224703\], and gwep1423 \[nct02224690\]. key exclusion criteria: * participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including sativex®) within the 3 months prior to study entry other than the investigational medicinal product (imp) received during the core study and are unwilling to abstain for the duration for the study. * any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the columbia-suicide severity rating scale (c-ssrs) at visit 1. * participant has been part of a clinical trial involving an imp during the inter-study period. * female participant is of child bearing potential or male participant's partner is of child bearing potential, unless willing to ensure that they or their partner use highly effective contraception, for example, hormonal contraceptives, intrauterine devices/hormone-releasing systems, bilateral tubal occlusion, vasectomized partner or sexual abstinence, during the study and for 3 months thereafter (however, a male condom should not be used in conjunction with a female condom). * participant has significantly impaired hepatic function at the 'end of treatment' visit of their core study or at visit 1 if re-assessed: i) alanine aminotransferase (alt) or aspartate aminotransferase (ast) \>5 × upper limit of normal (uln); ii) alt or ast \>3 × uln and (total bilirubin \[tbl\] \>2 × uln or international normalized ratio \[inr\] \>1.5); iii) alt or ast \>3 × uln with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\>5%). this criterion must be confirmed prior to entering the study.

Keywords: cannabidiol cbd gwp42003-p gwpcare5
evaluation of physiological and vocal parameters in volunteers of both genders submitted to an anxiogenic task

Conditions: Anxiety; Communication

Summary: objective: to assess whether the anxiety caused by a task considered anxiogenic, simulated public speaking (sps) test, would change the responses of healthy individuals regarding physiological and vocal parameters. method: the sample comprised 30 participants of both genders, 19-42 years old, with no history of psychiatric disorders. the score in the stai-trait enabled investigators to assign participants to two groups: low anxiety (la) and high anxiety (ha). the investigators evaluated physiological parameters (heart rate, skin conductance, temperature in the extremities, electromyogram of the frontal muscle and salivary cortisol) and vocal parameters (vocal self-evaluation, quality of life in voice and vocal symptoms and signs) before, during and after the sps.


Eligibility criteria:
inclusion criteria: * aged 18 to 45 years * volunteers with no psychiatric history and diagnosis of vocal problem * have a minimum of the average school exclusion criteria: * chronic smokers * subjects with paralysis or neurological diseases * compromised upper airway at the time of the experiment * user stimulants, psychotropic drugs, herbal medicines, tranquilizers, antidepressants * have drunk coffee or alcohol on the day of the experiment

Keywords: behavior anxiety communication voice
project health link: connecting patients with services

Conditions: Drug Abuse

Summary: the proposed study will compare three alternative interventions in the emergency department (ed) to promote linkage to substance abuse assessment, referral and treatment entry for those who meet abuse/dependence criteria for stimulants, cannabis, and/or non-injected opioids: (1) a 5-session strengths-based case management (sbcm) model; (2) a 2-session brief motivational enhancement (bme); or (3) a one-time brief informational feedback (bif) session. the primary outcome variables for this trial include receiving an assessment and referral and treatment entry. other outcomes include degree of treatment completion, substance-related measures, health service utilization, health status changes, and psychosocial factors.


Eligibility criteria:
inclusion criteria: * (1) adults age 19-60 presenting to the hurley medical center ed within 24 hours of an injury; (2) ability to provide informed consent. additional inclusion criteria for intervention study: meets criteria for substance abuse or dependence for stimulants (cocaine powder, crack cocaine, methamphetamine, amphetamine), cannabis (marijuana, hashish), and or opioids (noninjected heroin, other opioids such as hydrocodone and oxycodone) in the previous year. exclusion criteria: * (1) adult patients who do not understand english; (2) prisoners; (3) adults classified by medical staff as "level 1 trauma"; (4) adults deemed unable to provide informed consent as stated above (e.g., intoxication, mental incompetence); (5) patients treated in the ed for suicide attempts and sexual assaults; (6) patients who have been in treatment for substance abuse in the past six months; (7) patients who are triaged to psychiatric emergency services; and (8) patients who report injecting heroin or other opiates in the past year.
iso-osmolar vs. low-osmolar contrast agents for optical coherence tomography

Conditions: Coronary Artery Disease; Contrast Media Reaction

Summary: the proposed study aims to compare (a) volume contrast administered for optical coherence tomography (oct) imaging, (b) length of clear oct images, and (c) electrocardiographic changes immediately after contrast injection between iso-osmolar and low-osmolar contrast agents. the proposed study is a prospective, single-centered, randomized controlled, study that will compare an iso-osmolar vs. a low-osmolar contrast agent in patients undergoing clinically indicated coronary oct imaging. each patient will be randomized to oct acquisition.

patients referred to the cardiac catheterization laboratory for clinically indicated coronary angiography and coronary oct imaging will be identified by a study team member and screened for eligibility. the proposed study is a prospective, single-center, randomized, controlled, study that will compare an iso-osmolar vs a low-osmolar contrast agent in patients undergoing clinically-indicated coronary oct imaging. each patient will be randomized to oct acquisition. eligible patients will be approached to obtain informed consent by a member of the study team. once consent is obtained and inclusion and exclusion criteria are verified, patients are randomized to undergoing oct image acquisition with iso-osmolar contrast media(iocm) first or with low-osmolar contrast media first (locm). then the patients undergo coronary angiography and oct imaging as per clinical standard of care. however, during the oct imaging acquisition based on their randomization assignment the patient will undergo the 1st oct imaging run with either iso-osmolar contrast media or with low-osmolar contrast media. following this a 2nd oct imaging run of the same coronary vessel will be done using the other contrast media that was not used during the first run. therefore, each patient will serve as a comparator to themselves, but also to each other. the electrocardiogram will be recorded during and for 30 seconds after each injection and analyzed offline for detection of any changes

Eligibility criteria:
inclusion criteria: 1. age 18 years or greater 2. willing and able to give informed consent. the patients must be able to comply with study procedures 3. undergoing clinically-indicated coronary angiography and oct exclusion criteria 1. baseline electrocardiographic changes hindering interpretation (such as left bundle-branch block, and \>1 mm st segment depression) 2. emergency cardiac catheterization (for example in patients with st-segment elevation acute myocardial infarction) 3. inability to provide symptomatic assessment 4. known allergy to contrast

Keywords: optical coherence tomography contrast agents
metformin in older adults with type 2 diabetes (amemet)

Conditions: Diabetes Mellitus, Type 2

Summary: multicentric, observational, cross-sectional study in italy. the aims are to evaluate the daily metformin prescribed dose and the impact of renal function and concomitant medication in diabetic patients over 65 years.

the study was commissioned by the italian association of clinical endocrinologists (association of medical endocrinologists - ame) and approved by the ethical committee of cuneo hospital. the research was open to all specialists taking care of patients with diabetes in italy. the primary endpoint was the evaluation of metformin dosage. secondary endpoints were the relationship between the metformin dosage and the renal filtration rate and the relationship between the metformin dosage and the concomitant medication. an ad hoc form was developed and used to record all medical findings. the form was emailed to all participating centers who then emailed or faxed it back to the investigator's data manager. data were checked for accuracy. the following data were required: age, gender, body weight and height, diabetes duration, type of metformin (classical/slow), daily dosage of metformin, reported side effects,concomitant medications. serum creatinine and hba1c levels obtained within the previous two months were also required. each participating center recruited about 50 diabetic outpatients. inclusion criteria were as follows: adult outpatients ≥ 65 years with t2 diabetes mellitus, using metformin for at least six months, usually assuming three daily meals, and capable of informed consent.

Eligibility criteria:
inclusion criteria: * adult outpatients (≥65 years); * t2 diabetes mellitus; * taking metformin for at least six months; * assuming three daily meals; * capable of informed consent. exclusion criteria: * severe liver or renal failure (egfr \<30 ml/min/1.73 m2); * hospitalization for any cause in the last six month; * glucocorticoid treatment in the last six month; * oncologic treatment in the last six month; * ramadan in the last six months.